Jonathan Anderman
Known title: Gen Counsel & Corporate SecCIK: 0002032625
Jonathan Anderman's purchase track record
Jonathan Anderman has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/7/2025 | CMPX | $31K | +68.2% | +133.8% | +33.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CMPX | ▲ Buy | Grant | 25,000 | $47K | 4/29/2026 | View on chart |
| CMPX | ▲ Buy | Grant | 150,000 | $776K | 1/2/2026 | View on chart |
| CMPX | ▲ Buy | Open Market | 20,000 | $31K | 4/7/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Compass Therapeutics faces analyst downgrades after FDA setback
Compass Therapeutics is facing renewed scrutiny following an FDA setback for tovecimig, which H.C. Wainwright described as a risky filing strategy. Several firms, including Citizens, Guggenheim, and Craig-Hallum, lowered their price targets to $4 or $8 while maintaining positive ratings. The stock's RSI is near 20.7, indicating it is currently trading in oversold territory.
Compass Therapeutics faces analyst downgrades after FDA setback. Compass Therapeutics is facing renewed scrutiny following an FDA setback for tovecimig, which H.C. Wainwright described as a risky filing strategy. Several firms, including Citizens, Guggenheim, and Craig-Hallum, lowered their price targets to $4 or $8 while maintaining positive ratings. The stock's RSI is near 20.7, indicating it is currently trading in oversold territory.